Ergoteles LLC Iveric Bio, Inc. Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $23 Million - $34.8 Million	878,359 New	878,359 $34.6 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $357,256 - $706,531	38,006 New	38,006 $682,000
Q1 2022 May 13, 2022	SELL	$12.15 - $16.83 $1.2 Million - $1.66 Million	-98,520 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $1.36 Million - $1.85 Million	98,520 New	98,520 $1.65 Million
Q1 2021 May 12, 2021	SELL	$5.08 - $6.89 $163,576 - $221,858	-32,200 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$5.65 - $7.66 $181,930 - $246,652	32,200 New	32,200 $223,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.